Rhizen Pharmaceuticals
A Swiss biopharmaceutical company developing next-generation medicines for cancer and inflammation.
Last updated September 1, 2026
AI crawler reads
2requests
1companies- Anthropic2
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Rhizen Pharmaceuticals is a biopharmaceutical company based in La Chaux-de-Fonds, Switzerland. The company focuses on developing differentiated products through cutting-edge science and strategic partnerships, with a pipeline targeting cancer and inflammation.
History
Rhizen Pharmaceuticals was established in 2008 as a discovery and development company. It progressed to focus on oncology and inflammation, and has developed an early-stage pipeline. The company has entered into partnerships, including a licensing deal with Novartis AG for RP6557 for non-oncology indications, and has advanced assets such as Tenalisib and RP12146 into clinical trials.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/rhizen-pharmaceuticals-switzerland · Editorial policy · How profiles are compiled